Last checked at 25 Mar 2024 07:00
25 March 2024
Futura Medical plc
("Futura" or the "Company")
Notice of Results and Investor Presentation
Futura Medical plc (AIM: FUM), the consumer healthcare company behind Eroxon, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, will announce its results for the year ended 31 December 2023 on Wednesday 10 April 2024.
James Barder, Chief Executive Officer and Angela Hildreth, Finance Director will provide a live presentation for investors via the Investor Meet Company platform on 10 April 2024, at 09:00 BST.
The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via the Investor Meet Company dashboard up until 09:00 BST the day before, or at any time during the live presentation.
Investors can register for the presentation via the following link: https://www.investormeetcompany.com/futura-medical-plc/register-investor
Investors who already follow Futura Medical plc on the Investor Meet Company platform will automatically be invited.
Contacts:
Futura Medical plc
| James Barder Chief Executive Officer Angela Hildreth Finance Director and COO
| investor.relations@futuramedical.com +44 (0)1483 685 670 www.futuramedical.com
|
Liberum Nominated Adviser and Broker
| Phil Walker Ben Cryer Nikhil Varghese | +44 (0)20 3100 2000
|
| ||
Stifel Nicolaus Europe Limited Joint Broker
| Alan Selby Ben Maddison
| +44 (0)207 710 7600
|
| ||
Alma Strategic Communications | Rebecca Sanders-Hewett Sam Modlin Will Ellis Hancock | +44 (0)20 3405 0205 futura@almastrategic.com |
Notes to Editors:
Futura Medical plc (AIM: FUM) is the developer of innovative sexual health products, including lead product Eroxon. Our core strength lies in our research, development and commercialisation of topically delivered gel formulations in sexual health products.
Eroxon, Futura's clinically proven lead product, has been developed for the treatment of Erectile Dysfunction ("ED"). The highly differentiated product, which is the only topical gel treatment for ED available over the counter and helps men get an erection in ten minutes, addresses significant unmet needs in the ED market.
ED impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40.
Futura has distribution partners in place in a number of major consumer markets including Haleon in the US, the largest market for ED in the world, and Cooper Consumer Health in Europe. Eroxon has been nominated for a number of healthcare industry awards and has won two to-date.